BACKGROUND: Metastatic @entity5 are rare but some @entity1 have a prolonged survival. A new functional imagery now makes it possible to supplement the assessment of the extent of disease. OBSERVATION: A 57 year old @entity1 was referred for dyspnoea on exertion revealing an upper @entity5 , with @entity4303 . The assessment enabled to find out a @entity4303 tumour with liver and bone @entity3 , highlighted by positron-emission tomography and pentetreotide SPECT. A chemotherapy proved to be ineffective and upper left lobectomy was carried out because of the risk of @entity891 . The @entity1 was treated by @entity1943 analogues then underwent liver transcatheter arterial chemo-embolization. The @entity1 was alive 44 months after diagnosis (56 months after first computed tomography). CONCLUSION: Metastatic @entity5 are rare. They keep a metastatic potential, the histological type remaining the major prognosis factor. @entity4303 is suggestive. The assessment of extra-thoracic disease extent benefits by contribution of new functional imagery techniques such as the pentetreotide SPECT and positron-emission tomography. The management is essentially symptomatic since there is no effective chemotherapy. However survival can be prolonged, even in multimetastatic @entity1 .

[Primitive metastasizing XXXX with long survival].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['left lobar tumour', 'bronchial carcinoid tumours'] @entity891 :: ('MESH:D001261', 'Disease') :: ['pulmonary atelectasis'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity4303 :: ('MESH:D002276', 'Disease') :: ['bronchial carcinoid', 'carcinoid syndrome', 'Carcinoid syndrome'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin']
@entity4303 :: (MESH:D002276,Disease) :: ['bronchial carcinoid']
